Alimera Sciences (NASDAQ:ALIM) Downgraded to Hold at StockNews.com

StockNews.com cut shares of Alimera Sciences (NASDAQ:ALIM) from a buy rating to a hold rating in a research note released on Tuesday morning.

Separately, Maxim Group initiated coverage on Alimera Sciences in a research note on Monday, March 25th. They set a buy rating and a $10.00 price target on the stock.

Alimera Sciences Stock Up 0.3 %

Alimera Sciences stock opened at $3.68 on Tuesday. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.39 and a quick ratio of 2.31. Alimera Sciences has a fifty-two week low of $1.56 and a fifty-two week high of $4.38. The firm has a fifty day moving average price of $3.73 and a two-hundred day moving average price of $3.65. The firm has a market cap of $192.65 million, a price-to-earnings ratio of -1.70 and a beta of 1.18.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.09). Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. The business had revenue of $26.31 million for the quarter, compared to analyst estimates of $25.10 million. During the same period in the prior year, the firm posted ($0.54) EPS. As a group, analysts forecast that Alimera Sciences will post 0.03 earnings per share for the current year.

Hedge Funds Weigh In On Alimera Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AIGH Capital Management LLC bought a new position in Alimera Sciences in the 3rd quarter worth approximately $7,355,000. Stonepine Capital Management LLC bought a new stake in shares of Alimera Sciences during the 3rd quarter valued at $12,349,000. Finally, Worth Venture Partners LLC acquired a new position in shares of Alimera Sciences in the 3rd quarter valued at $1,840,000. 99.83% of the stock is currently owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).